linjc16/ctgov huggingface dataset:
Clinical Evaluation of Four Aesthetic Restorations in Non-carious Cervical Lesions

Study Overview
=================
Brief Summary
-----------------
To compare the clinical performance of high-viscosity glass ionomer, flowable composite, bulkfill composite and nanohybrid composite restorations in non-carious cervical lesions (NCCLs).

Detailed Description
-----------------
One hundred fourty NCCLs were randomised into four groups according to a split-mouth design. Clinical evaluations will be performed after 1 week, 3 months, 6 months, using FDI (World Dental Federation) criteria.

Official Title
-----------------
Clinical Evaluation of Four Aesthetic Restorations in Non-carious Cervical Lesions: a Randomised Controlled Split-mouth Clinical Trial

Conditions
-----------------
Noncarious Cervical Lesions

Intervention / Treatment
-----------------
* Other: EQUIA Forte Fil
* Other: Clearfil Majesty Esthetic
* Other: NexComp Flow
* Other: 3M Espe Bulk-fill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: had at least four non-carious symmetrical cervical lesions, had permanent dentition and were older than 20 years old, had cervical margins in dentin Exclusion Criteria: periodontal disease pregnant or breastfeeding being under orthodontic therapy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High-viscosity glass ionomer<br> | Other: EQUIA Forte Fil<br>* Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s unit<br>|
| Experimental: flowable composite<br> | Other: NexComp Flow<br>* Apply in 2-mm increment light cure for 20 s<br>|
| Experimental: bulkfill composite<br> | Other: 3M Espe Bulk-fill<br>* Apply in single increment up to 4 mm; light curing for 20 s<br>|
| Experimental: nanohybrid composite<br> | Other: Clearfil Majesty Esthetic<br>* Apply in 2-mm increment, light cure for 20 s<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of restoration on cervical lesions | According to FDI criteria (aesthetic, biological and fuctional) score 1, clinically very good; score 2, clinically good; score 3, clinically sufficient; score 4, clinically unsatisfactory; score 5, clinically poor. Scores 1-3 show clinically acceptable restoration, while scores 4 and 5 indicate failure | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
High-viscosity glass ionomer, bulkfill composite, flowable composite, nanohybrid composite, cervical lesion
Medications Effect on Lenstar Measurements

Study Overview
=================
Brief Summary
-----------------
Prior to cataract surgery the lens must be calculated to appropriately fit a patient for the intraocular lens implant. Lenstar is an optical biometer that calculates the axial length, keratometry, lens thickness, pupillometry, and anterior chamber depth. Dilation drops are routinely used in eye exams in addition to pre-cataract surgery. The dilation drops include Tropicamide 1%, and Phenylephrine 2.5%. The Tropicamide achieves the dilation of the pupil which causes an anterior rotation of the ciliary body, which may affect the Lenstar measurements. This study is to determine if dilating medications affect the lens power prediction for emmetropia by the Lenstar biometer. Prior to dilation, Lenstar biometry will be performed on each eye. Patients will receive dilation medication and after waiting 20 minutes Lenstar biometry will be performed on each eye. Dilation and measurement with Lenstar will be done as standard of care. Measurements and calculations from before and after will be compared.

Official Title
-----------------
The Effects of Dilation Medication on Lenstar Measurements for Cataract Surgery

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Other: Lenstar Biometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Candidates for cataract surgery undergoing routine evaluation of cataracts. Exclusion Criteria: Patients that have had their cataracts removed Patients that cannot undergo routine evaluation for cataract surgery (because they are too ill to sit upright in a chair)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lenstar Biometry<br>Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time. | Other: Lenstar Biometer<br>* uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baseline Lens Power will be compared to Post dilation measurements using Lenstar biometer |  | One Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dilation, Intraocular, Ophthalmology
Prizma Device Temperature Measurement

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the temperature measurements by the Prizma device.

Detailed Description
-----------------
Primary objective of this study is to compare the temperature measured by the PRIZMA to the oral and Armpit temperature measured by a gold standard device in order to develop and evaluate a skin to body temperature conversion table. Secondary objective is to collect and compare data of ECG, Respiration and SpO2 collected from the Prizma device to the data collected from gold standard devices for reference of noise level and for future development of the PRIZMA device.

Official Title
-----------------
Clinical Evaluation for Body Temperature Measurement Using Prizma Smart Phone Cover and Application

Conditions
-----------------
Temperature Change, Body

Intervention / Treatment
-----------------
* Device: Prizma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent Age above 18 years from both genders ASA physical status 1-4 Hospitalized in internal ward Exclusion Criteria: Abuse of alcohol or illicit drugs History of mental retardation or any mental disease Skin irritation / Atopic dermatitis or any other skin condition at the area of patients palms that might affect his/her ability to hold the device appropriately

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Prizma|sensor unit with mobile application installed on smartphone|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Temperature measurement | Develop and evaluate a skin to body temperature conversion table. | 3 months |
Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate if the use of antidepressant medication in depressed patients with implantable cardioverter defibrillator reduces the number of ICD's shocks as it improves depressive affect.

Detailed Description
-----------------
episodes of arrhythmia remain present even after icd implantation, this is specially true in depressed patients. it is hypothesized that improving mood state by means of an antidepressant drug . namely mirtazapine. could be responsible of alleviating the number of appropriate shocks delivered by the cardioverter. this could be due to a direct effect of the drug itself or an indirect effect of improving anxious and depressive affect. the mood and anxiety state are measured with the HADS scale

Official Title
-----------------
Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety

Conditions
-----------------
Depression, Anxiety

Intervention / Treatment
-----------------
* Drug: mirtazapine
* Drug: mirtazapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cardioverter implanted patients depression anxiety Exclusion Criteria: heart failure other diseases reducing physical fitness

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 87 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: mirtazapine<br> | Drug: mirtazapine<br>* mirtazapine 15 mg daily tablets<br>* Other names: mirtazapine 1500 mtz;Drug: mirtazapine<br>* 15 mg daily<br>* Other names: remeron 1569 rem;|
| Placebo Comparator: mirtazapine, sugar pill<br> | Drug: mirtazapine<br>* 15 mg daily<br>* Other names: remeron 1569 rem;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of implantable cardioverter defibrillator shocks |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement of depression |  | one year |
To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

Study Overview
=================
Brief Summary
-----------------
After successful screening of liver cirrhosis patients attending ILBS OPD for signs of parkinsonism ( tremor, rigidity or bradykinesia, any 2 of 3). Diagnosis of hepatic/cirrhosis related parkinsonism will be made. Patients will be randomized into Bromocriptine and Placebo. Patients will be followed up every month in OPD (Out Patient Department), ILBS (Institute of liver & Biliary Sciences) for 3 months. Detailed neurological examination will be done at each visit & UPDRS (Unified Parkinson's Disease Rating Scale ) score will be calculated.

Official Title
-----------------
A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

Conditions
-----------------
Cirrhosis Related Parkinsonism

Intervention / Treatment
-----------------
* Drug: Lactulose+Rifaximin +Bromocriptine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cirrhosis of liver with signs of parkinsonisms Patients consented for the study protocol by signing the informed consent. Exclusion Criteria: Age < 18 years. Patient s with HCC (Hepatocellular Carcinoma). Patients diagnosed as Wilsons disease. Patient who withdrew or non complaint to the study protocol. ALF (Acute Liver failure) Classical Parkinsonism Atypical Parkinsonism Pregnancy Hypotension Uncontrolled hypertension CAD Psychiatric illness Acute episode of Hepatic encephlopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lactulose + Rifaximin + Bromocriptine<br> | Drug: Lactulose+Rifaximin +Bromocriptine<br> <br> |
| Active Comparator: Lactulose+Rifaximin+Placebo<br> | Drug: Lactulose+Rifaximin +Bromocriptine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome will be decrement in UPDRS (Unified Parkinson's Disease Rating Scale) score by 30 %. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary end point will be decrement in UPDRS (Unified Parkinson's Disease Rating Scale) score of 10% to 30%. |  | 3 months |
Dexketoprofen Dosage According to Chronotherapy

Study Overview
=================
Brief Summary
-----------------
Lower third molar extraction is one of the most common treatments in oral surgery practice. It is a treatment with inherent complications such as postoperative pain, swelling or trismus. In order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. Recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration. The aim of the study is to analyze if dosage modification of a Non Steroideal Anti-Inflammatory (dexketoprofen) affects on postoperative pain, swelling and open mouth limitation according the circadian clock

Detailed Description
-----------------
A randomized crossover split-mouth clinical trial will be performed. After third molar extractions, patients will be prescribed randomly in one side intake morning medication dosage while the contralateral side will be prescribed a night dosage. Moreover, a blood sample will be obtained to analyze the inflammatory profile.

Official Title
-----------------
Efficacy of Dexketoprofen Prescribed According to the Circadian Rhythms

Conditions
-----------------
Trismus, Tooth, Impacted, Pain, Inflammatory Response

Intervention / Treatment
-----------------
* Drug: Dexketoprofen 25 MG
* Drug: Dexketoprofen 25 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral impacted lower third molar Exclusion Criteria: NSAID allergic Contraindication of surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Morning dosage<br>Dexketoprofen pill at morning; Placebo at night | Drug: Dexketoprofen 25 MG<br>* Pill at morning<br>* Other names: Morning dosage;|
| Experimental: Night dosage<br>Placebo pill at morning; Dexketoprofen at night | Drug: Dexketoprofen 25 MG<br>* Pill at night<br>* Other names: Night dosage;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post operatory pain | Postoperatory pain with Visual Analogue Scale (VAS: 0 (no pain) to 10 (worst pain)) | From the day of the surgical procedure to the seventh-day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Swelling | Distance from tragus to pogonion | Baseline and post operatory (day 1, day 3, day 7) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Third, Dexketroprofen, Randomized
Continuous Fetal Monitoring During Vacuum Delivery

Study Overview
=================
Brief Summary
-----------------
The investigators have added an additional electrode to the vacuum device for birth in which they can monitor the fetus during delivery.

Detailed Description
-----------------
The investigators have added an additional electrode to the vacuum device for birth in which they can monitor the fetus during delivery. The electrode is a standard one inserted in the vacuum device.

Official Title
-----------------
Continuous Fetal Monitoring During Vacuum Delivery an Addition of a New Device

Conditions
-----------------
Vacuum Delivery

Intervention / Treatment
-----------------
* Device: Agit Vacuum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All fetuses at vacuum delivery Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electrode added to device<br>With an electrode and a regular vacuum device | Device: Agit Vacuum<br>* With an electrode and a regular vacuum device<br>* Other names: Agit Vaccum;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of fetal heart rate monitoring in both arms |  | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
electrode vacuum delivery
Recombinant Factor VII for Intractable Postpartum Haemorrhage

Study Overview
=================
Brief Summary
-----------------
Postpartum haemorrhage remains at the top of the causes of maternal deaths in both developed and developing countries .

Detailed Description
-----------------
Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

Official Title
-----------------
Recombinant Factor VII for the Conservative Management Trials of Intractable Postpartum Haemorrhage: is it a Drug Effect , Operator Experience or Inherent Result of the Aetiology.

Conditions
-----------------
Post Partum Hemorrhage

Intervention / Treatment
-----------------
* Drug: recombinant factor VIIa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with severe resistant postpartum hemorage Exclusion Criteria: women without postpartum hemorage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Junior staff has started the management and called for the senior staff.<br> | Drug: recombinant factor VIIa<br>* using recombinant factor VIIa<br>|
| senior staff. managed the case from the start<br> | Drug: recombinant factor VIIa<br>* using recombinant factor VIIa<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of women who had hysterectomy | number of women resistant to the treatment and needed hysterectomy | 24 hours |
Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms

Study Overview
=================
Brief Summary
-----------------
Based on the Individualized treatment of diabetes symptoms to evaluate the method of syndrome differentiation treatment of Traditional Chinese medicine.

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Chinese herbal medicine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed type 2 diabetes poorly controlled by diet and exercise therapy, and must with any of diabetes symptoms. After the diet and exercise therapy, 7.0mmol/l≤FPG≤11.1mmol/l or 8.0mmol/l<2h PG<16mmol/l Any type of TCM syndrome, but can be performed within the chosen Chinese herbal medicine. Subject is willing to participate and capable of giving informed consent. Exclusion Criteria: Those patients used any drugs for treatment of diabetes within one month. Patients with any severe complications of cardiac, cerebric, vascular, hepatic, renal, blood system. Patients suffer from acute metabolic disorder including diabetic ketoacidosis or hyperosmotic non-ketotic coma within one month. Women who were pregnant, lactating or planned pregnant. Allergic constitution and has a history of drug allergy. Combined with severe acute or chronic infections.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chinese herbal medicine<br>Individualized Treatment with Chinese herbal | Drug: Chinese herbal medicine<br>* According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.<br>|
| Placebo Comparator: Placebo<br>Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine. | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Total score of diabetes symptoms at 4 weeks |  | 0 weeks(baseline), 2 weeks, 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Fasting Blood Glucose at 4 weeks |  | 0 weeks(baseline), 2 weeks, 4 weeks | 
| Change from Baseline blood glucose at 2 hours after meal at 4 weeks |  | 0 weeks(baseline), 2 weeks, 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes symptoms, Chinese herbal medicine